Growth hormone and IGF-1 elevation
In two randomised, double-blind, placebo-controlled, ascending-dose trials in healthy adults (age 21 to 61), lasting 28 and 49 days, the first gave one of four ascending single doses and the second gave 2 or 3 weekly or biweekly doses of subcutaneous CJC-1295 with DAC. After a single injection, mean growth hormone rose 2- to 10-fold for 6 days or more and mean IGF-1 rose 1.5- to 3-fold for 9 to 11 days, rising with dose. After multiple doses, mean IGF-1 stayed above baseline for up to 28 days.
- Study type
- Human trial
- Population
- Human, healthy adults aged 21-61, two randomised placebo-controlled ascending-dose trials (ascending single doses in the first; 2 or 3 weekly or biweekly doses in the second)
- Source
- 1 Teichman et al., 2006
Limitation: Two short trials (28 and 49 days) of single or a few repeated doses, not chronic dosing.
Limitations in full
Two short trials (28 and 49 days) of single or a few repeated doses, not chronic dosing. Randomised and placebo-controlled, but not independently replicated, and no chronic-dosing efficacy trial was identified. This is the only human trial report cited on this page, and it measures hormone levels rather than a clinical outcome. Evidence strength is rated Limited.